Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-08

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1, open-label, sequential ascending dose-escalation study. Designed to evaluate the safety and efficacy of a single IV infusion of investigational gene therapy HMI-203. Males, ages 18 to 45 years inclusive, with MPS II (Hunter syndrome) currently receiving idursulfase ERT (or the equivalent) are eligible to participate. Participants will be followed for safety and efficacy for 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gene Therapy Clinical Study in Adult PKU

NCT03952156

Phenylketonurias PAH Deficiency

TERMINATED PHASE1/PHASE2

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

NCT05222178

Phenylketonurias PAH Deficiency Phenylketonuria

TERMINATED PHASE1

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

NCT04007536

Mucopolysaccharidosis II

COMPLETED

Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)

NCT00004454

Mucopolysaccharidosis II

COMPLETED PHASE1/PHASE2

Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type II

NCT05665166

Mucopolysaccharidosis II

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase 1 study will evaluate the safety and efficacy of HMI-203 gene therapy in adult male participants with MPS II currently being treated with standard-of-care idursulfase ERT or equivalent. Participants will receive a single dose of HMI-203 administered intravenously. There are 3 planned dose cohorts which will consist of 3 participants each.

Entry into the first dose cohort will be separated by a 60-day dosing interval between each participant to allow the Homology Medicines medical monitor to review safety and efficacy data prior to the second and third participants being enrolled. Enrollment of subsequent participants, in cohorts 2 and 3, will be separated by a 21-day dosing interval between each participant for review of safety and efficacy data.

Escalation to the next dose cohort will occur after 21 days of safety, efficacy, and biomarker data have been reviewed by the Homology Medicines independent DMC.

This entire study is comprised of 5 years, with the most frequent follow up visits occurring in the first year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucopolysaccharidosis II

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HMI-203 Low Dose Level Cohort 1

Group Type EXPERIMENTAL

Genetic HMI-203

Intervention Type BIOLOGICAL

HMI-203 delivered intravenously

HMI-203 Intermediate Dose Level Cohort 2

Group Type EXPERIMENTAL

Genetic HMI-203

Intervention Type BIOLOGICAL

HMI-203 delivered intravenously

HMI-203 High Dose Level Cohort 3

Group Type EXPERIMENTAL

Genetic HMI-203

Intervention Type BIOLOGICAL

HMI-203 delivered intravenously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic HMI-203

HMI-203 delivered intravenously

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult males 18-45 years of age at the time of informed consent
* Has capacity and is able to understand the purpose and risks of the study and is willing, able and committed to comply with all study procedures for the duration of the trial (a total of 5 years after gene therapy administration)
* Diagnosis of MPS II based on historically decreased I2S enzyme activity and elevated urine GAGs and/or presence of hemizygous IDS pathogenic variant
* Kaufman Brief Intelligence Test-Second Edition (KBIT2) score ≥ 80
* Compliance with regular treatments of ERT for MPS II for at least 12 months prior to enrollment
* Clinically stable relative to urinary GAG levels, ambulation, and cardiopulmonary status for 12 months preceding enrollment

Exclusion Criteria

* Multiple sulfatase disorder as determined by abnormal activity of another lysosomal sulfatase
* Unresponsive and/or intolerant to idursulfase treatment
* History of BMT, stem cell transplant, or gene therapy
* Presence of anti-capsid neutralizing antibodies
* ALT or AST \> ULN; Total or Direct bilirubin \> ULN
* International normalized ratio (INR) \>1.2 ULN
* Hematology values below the normal range
* Hemoglobin A1c ≥ 6.5% or fasting glucose ≥126 mg/dL
* Contraindication to corticosteroid or tacrolimus use
* Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential participant unsuitable for the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No